Objective of this study is to 1) analyze the clinical, anatomical and periprocedural differences of patients who underwent a procedure related to coronary CTO through the antergrade approach and retrograde approach; 2) analyze the success rate of the procedures and the incidence and patterns of complications; 3) compare and analyze long-term performances after the successful procedure; and 4) identify the independent factors that require a retrograde approach and the prognostic factor regarding long-term performances after use of each approach.
Patients aged>=19
Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5 mm in blood vessel diameter
Patients who have symptoms of angina or objectively proven myocardial ischemia (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment elevation myocardial infarction)
Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or let their representative do this), and signed the informed consent form approved by the IRB of each study institute
Patients who are pregnant or lactating or have childbearing potential Patients in whom contrast medium and heparin are contraindicated or who are hypersensitive to them
Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are contraindicated
Patients scheduled to undergo a surgery, etc. that requires discontinuance of an antiplatelet drug within 12 months after participation in the study
Acute ST elevation myocardial infarction at the time of hospitalization
Subject selection will be determined after screening patients who undergo PCI for CTO lesions and completing the evaluation of all inclusion/exclusion criteria.
Cohort
Prospective
antegrade and retrograde approach
Procedure/SurgeryThis study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
Death
Death
myocardial infarction
the periprocedural myocardial infarction under the SCAI definition or the non-lethal myocardial infarction during the follow-up observations
the complex endpoints of target vessel revascularization/reocclusion occurrence
including chronic total occlusion and angiostenosis
Procedure success rate
A procedure success defined as the case where a final vessel diameter stenosis \< 30% is achieved after the stent insertion
Myocardial infarction
Q-wave VS non-Q-wave, periprocedural myocardial infarction VS follow-up myocardial infarction (spontaneous myocardial infarction
Click on the lead sponsor to view all of their trials.
Seung-Whan Lee, M.D., Ph.D.
Lead sponsor
Asan Medical Center
Sponsor institution
Abbott Medical Devices
Collaborator
Teleflex
Collaborator
Medtronic
Collaborator
Dio
Collaborator
